1442 completed, 569 unknown, 540 recruiting, 419 terminated. 1347 Phase 2, 1100 Phase 1, 494 Not applicable, 312 Phase 3, 125 Phase 4.
Follow this condition Literature Review of Recurrence trials Research Report on Recurrence
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Medically Supervised Ibogaine With 12-Month Digital Recovery Support for Opioid Use Disorder Ibogaine Hydrochloride, Extended-release naltrexone injection, 380 mg, Matching Oral Placebo - Opioid Use Disorder, Opioid Withdrawal | Phase 1 / Phase 2 | Not yet recruiting | Clive Michelsen | 60 | 2027-07-01 | 2026-10-13 |
| Metronomic Temozolomide With Dexbrompheniramine for Recurrent High-Grade Glioma/Glioblastoma Dexbrompheniramine, Temozolomide - High Grade Glioma, Glioblastoma | Phase 1 / Phase 2 | Not yet recruiting | University of Nebraska | 41 | 2027-06-01 | 2026-10-05 |
| Phase I Safety Clinical Trial of Anti-CD19 CAR-T Therapy COL01 for the Treatment of Adults With Relapsed or Refractory B-cell Lymphoid Neoplasms: First-in-human Administration, COLIBRI. CAR-T anti-CD19 COL01 - Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia, Lymphoid Malignancies | Phase 1 | Not yet recruiting | GUSTAVO SALGUERO | 12 | 2027-04-01 | 2026-10-20 |
| A Study of Remibrutinib Using MR Imaging in Relapsing or Progressive MS Remibrutinib (Open Label) - Multiple Sclerosis (MS) - Relapsing-remitting, Multiple Sclerosis (MS) Secondary Progressive | Phase 2 | Not yet recruiting | Moein Amin | 20 | 2027-03-01 | 2026-08-19 |
| Teclistamab In Waldenstrom's Macroglobulinemia Teclistamab - Waldenstrom's Macroglobulinemia | Phase 2 | Not yet recruiting | Massachusetts General Hospital | 24 | 2027-02-19 | 2026-09-01 |
| RAPID: Phase 2 Platform Trial Of Promising Drugs For AYA Patients With R/R Ewing Sarcoma & DSRCT LX-101 - Ewing Sarcoma | Phase 2 | Not yet recruiting | M.D. Anderson Cancer Center | 120 | 2027-02-01 | 2026-08-24 |
| Phase 1 Dose Escalation Study of RXIM002 in Autoimmune Cytopenias RXIM002 - Immune Thrombocytopenia (ITP) | Phase 1 | Not yet recruiting | RiboX Therapeutics Ltd. | 27 | 2027-02-01 | 2026-09-23 |
| Roginolisib Plus Obinutuzumab + Venetoclax in R/R CLL Roginolisib, Obinutuzumab, Venetoclax - Chronic Lymphocytic Leukemia (CLL), Refractory Chronic Lymphocytic Leukemia | Phase 1 / Phase 2 | Not yet recruiting | Dana-Farber Cancer Institute | 40 | 2027-01-13 | 2026-09-29 |
| A Study of Cladribine, Low Dose Cytarabine, and Venetoclax in Treatment of Relapsed/Refractory or Secondary Acute Myeloid Leukemia CAV - Acute Myeloid Leukemia (AML) | Phase 2 | Not yet recruiting | University of Rochester | 24 | 2026-12-31 | 2026-10-16 |
| A Multicenter Study of Belantamab Mafodotin and Mezigdomide in Patients With Relapsed Multiple Myeloma CAR-T cells, BCMA bispecific - Myeloma Multiple | Phase 1 / Phase 2 | Not yet recruiting | Centre Hospitalier Universitaire de Saint Etienne | 44 | 2026-12-01 | 2026-10-09 |
| Phase 1a/1b Clinical Trials to Evaluate the Safety and Preliminary Efficacy of GNTbm-38. GNTbm-38 - Solid Tumor (Phase I), Relapsed or Refractory Peripheral T-cell Lymphoma (PTCL) | Phase 1 | Not yet recruiting | Great Novel Therapeutics Biotech & Medicals Corporation | 70 | 2026-12-01 | 2026-09-25 |
| Mitoxantrone Hydrochloride Liposome Combined With Cladribine And Sotorasib For Relapsed Refractory Acute Myeloid Leukemia Mitoxantrone Hydrochloride Liposome+cladribine+sotoraclib - Relapsed and Refractory Acute Myeloid Leukemia (RR-AML) | Phase 2 | Not yet recruiting | The Affiliated People's Hospital of Ningbo University | 20 | 2026-12-01 | 2026-10-15 |
| BAFF CAR-T Cells (LMY-920) for Treatment of Relapsed or Refractory Non-Hodgkin Lymphoma and Multiple Myeloma BAFF CAR-T - Non-Hodgkin Lymphoma Refractory/ Relapsed, Multiple Myeloma Refractory | Phase 2 | Not yet recruiting | Luminary Therapeutics | 90 | 2026-12-01 | 2026-08-18 |
| Symptom Trajectory Approaches to Research Health surveys - Advanced Cancer, Metastatic Disease | Not yet recruiting | University of Wisconsin, Madison | 228 | 2026-12-01 | 2026-09-04 | |
| The GLIOMAX Study: MT027 Allogeneic CAR-T for Recurrent Glioma Intracerebroventricular injection of MT027 UCAR-T Cell targeting B7H3 - Glioblastoma IDH (Isocitrate Dehydrogenase) Wildtype | Phase 2 | Not yet recruiting | T-MAXIMUM Pharmaceutical Inc | 40 | 2026-11-30 | 2026-10-14 |
| A Study to Evaluate Adverse Events and Change in Disease Activity With Injected Etentamig Plus Oral Pomalidomide Versus Standard Therapies in Adults With Relapsed or Refractory Multiple Myeloma Etentamig, Pomalidomide, Daratumumab - Relapsed or Refractory Multiple Myeloma | Phase 3 | Not yet recruiting | AbbVie | 520 | 2026-11-30 | 2026-07-27 |
| Laser Interstitial Thermal Therapy (LiTT) With Cemiplimab or Other Chemotherapy in Recurrent Glioblastomas NeuroBlate® Laser Ablation Laser Interstitial Thermal Therapy, Cemiplimab, Chemotherapy - Glioblastoma, Glioblastoma, IDH-wildtype | Phase 2 | Not yet recruiting | Washington University School of Medicine | 99 | 2026-11-30 | 2026-10-20 |
| Venetoclax, Chidamide, and Chiglitazar Sodium (VCC) in Patients With Relapsed/Refractory Acute Myeloid Leukemia venetoclax, chidamide, and chiglitazar sodium (VCC) - Relapsed or Refractory Acute Myeloid Leukemia | Phase 2 | Recruiting | The First Affiliated Hospital of Xiamen University | 30 | 2026-11-11 | 2026-08-24 |
| Management of Non Emergency Adhesive Small Bowel Obstruction: Surgical group - SBO - Small Bowel Obstruction | Enrolling by invitation | Azienda Sanitaria di Firenze | 690 | 2026-11-01 | 2026-10-06 | |
| CD19/CD20 Dual-Target in Vivo CAR-T Lentiviral Product in the Treatment of Relapsed/Refractory B-cell Malignancies CD19/CD20 Dual-Target in vivo CAR-T Lentiviral - Relapsed/Refractory B-cell Malignancies | Phase 1 | Not yet recruiting | The First Affiliated Hospital with Nanjing Medical University | 80 | 2026-11-01 | 2026-08-13 |
Showing 20 of 3547. Sign in to see all of them.
Multiple Myeloma (400) · Leukemia, Myeloid, Acute (318) · Lymphoma (284) · Neoplasms (274) · Neoplasm Metastasis (254) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (249) · Lymphoma, Non-Hodgkin (244) · Lymphoma, Large B-Cell, Diffuse (239) · Leukemia, Lymphocytic, Chronic, B-Cell (211) · Leukemia (199) · Burkitt Lymphoma (187) · Hodgkin Disease (175) · Lymphoma, Follicular (169) · Lymphoma, Mantle-Cell (166)
Pathological Conditions, Signs and Symptoms (3547) · Pathologic Processes (3542) · Disease Attributes (3541) · Neoplasms (2232) · Neoplasms by Histologic Type (1885) · Hemic and Lymphatic Diseases (1430) · Immune System Diseases (1289) · Immunoproliferative Disorders (1143) · Lymphoproliferative Disorders (1139) · Neoplasms by Site (994) · Hematologic Diseases (962) · Lymphatic Diseases (869) · Cardiovascular Diseases (534) · Neoplasms, Glandular and Epithelial (511) · Vascular Diseases (499)
Cyclophosphamide (170) · Dexamethasone (151) · Rituximab (101) · fludarabine (96) · Cytarabine (81) · Lenalidomide (78) · Bortezomib (67) · Gemcitabine (67) · fludarabine phosphate (65) · venetoclax (60) · Etoposide (58) · pembrolizumab (55) · pomalidomide (55) · Carboplatin (50) · Cisplatin (49)
M.D. Anderson Cancer Center (62) · Celgene (53) · Novartis Pharmaceuticals (50) · Memorial Sloan Kettering Cancer Center (48) · National Cancer Institute (NCI) (39) · Sun Yat-sen University (36) · Fred Hutchinson Cancer Center (31) · AbbVie (26) · Assistance Publique - Hôpitaux de Paris (25) · Amgen (24) · Institute of Hematology & Blood Diseases Hospital, China (24) · AstraZeneca (22) · Pfizer (22) · Dana-Farber Cancer Institute (20) · H. Lee Moffitt Cancer Center and Research Institute (20)
United States (1452) · China (683) · France (386) · Spain (303) · Canada (295) · Italy (290) · Germany (286) · United Kingdom (221) · Australia (196) · South Korea (173) · Belgium (159) · Netherlands (131) · Japan (118) · Poland (114) · Taiwan (110)
Alison Moskowitz, MD (5) · Brenda Sandmaier (5)
PMID 34515338, PMID 32499241, PMID 41671463, PMID 26932146, PMID 30918100, PMID 31039052, PMID 31401903, PMID 32426039, PMID 35622074, PMID 22067384, PMID 22980441, PMID 23054212, PMID 23306310, PMID 24131282, PMID 24378877, PMID 24844673, PMID 26526385, PMID 26706103, PMID 27733070, PMID 28188133, PMID 28751099, PMID 28751558, PMID 28770420, PMID 29477379, PMID 29673108, PMID 31685558, PMID 32757523, PMID 33674274, PMID 33676197, PMID 33820822, PMID 34398557, PMID 34498507, PMID 34702811, PMID 35266417, PMID 35397664, PMID 35422096, PMID 35772429, PMID 35978286, PMID 36100310, PMID 36718018, PMID 37061656, PMID 37142273, PMID 37185961, PMID 37341961, PMID 37393120, PMID 37606897, PMID 38092009, PMID 38190117, PMID 38502198, PMID 39018512
2023 (50), 2015 (24), 2017 (20), 2018 (20), 2019 (19), 2016 (18), 2009 (15), 2014 (15), 2025 (15), P30CA015704 (13), 2008 (10), U01CA097452 (9), P30CA006973 (6), P30CA016672 (6), P30CA043703 (6)